Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Tarsus Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements XDEMVY™ 0.25% received FDA approval for the treatment for Demodex blepharitis"
08/02/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/25/2023 8-K Quarterly results
05/09/2023 8-K Quarterly results
Docs: "Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA"
04/24/2023 8-K Quarterly results
03/13/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA"
01/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2022 8-K Quarterly results
Docs: "Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements New Drug Application for TP-03 accepted&#59; PDUFA target action date August 25, 2023"
10/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/11/2022 8-K Quarterly results
Docs: "Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial&#59; NDA submission expected this year"
06/22/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/03/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/02/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Tarsus Pharmaceuticals, Inc. Corporate Presentation",
"Tarsus Pharmaceuticals, Inc. Corporate Presentation"
05/02/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tarsus Pharmaceuticals, Inc. Saturn-2 Clinical Results Summary",
"Tarsus Pharmaceuticals, Inc. Saturn-2 Clinical Results Summary"
03/14/2022 8-K Quarterly results
02/02/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
01/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation"
11/09/2021 8-K Quarterly results
Docs: "Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis&#59; topline data expected in the first quarter of 2022"
11/01/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors"
08/04/2021 8-K Quarterly results
Docs: "Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis&#59; results presented at the 2021 American Society of Cataract and Refractive Surgery conference"
06/22/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
11/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of the Securities Exchange Act of 1934 Date of Report : November 19, 2020 Tarsus Pharmaceuticals, Inc. Delaware 001-39614 81-4717861 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 409-9820 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R...",
"Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors"
11/17/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Tarsus Pharmaceuticals, Inc. November 17, 2020 Investor Presentation"
10/20/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of the Securities Exchange Act of 1934 Date of Report : October 20, 2020 Tarsus Pharmaceuticals, Inc. Delaware 001-39614 81-4717861 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 409-9820 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Ru...",
"Amended and Restated Certificate of Incorporation of Tarsus Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Tarsus Pharmaceuticals, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy